title: [Evaluation of breast HER2+ cancer pathologic response after a taxan plus trastuzumab-based chemotherapy].
abstract: OBJECTIVE
  In our study, we aimed to assess the pathologic complete response after neo-additive chemotherapy that contains a taxan associated to trastuzumab for patients treated from breast cancer at the institute Jean-Godinot between 2012 and 2014, and to evaluate factors associated to this pathologic complete response.
  
  
  METHODS
  Retrospective study with clinical, anatomopathologic and radiologic parameters analysis before and after new adjuvant chemotherapy. The statistical analysis was done on logiciel XL-STAT, the Mann-Whitney-Wilcoxon for quantitative variables and Fisher exact tests for qualitative variables, the Spearman rang test.
  
  
  RESULTS
  The rate of pathologic complete response is 38.8%. The prognostic factor associated to pathologic complete response is a Ki-67>44%.
  
  
  CONCLUSIONS
  The pathologic complete response rate corresponds to international lower rate; because of the lack of several data, we found out only one prognostic factor, Ki-67>44%.
authors.affiliation: Alix de champagne, service de gynécologie-obstétrique, CHU de Reims, 45, rue Cognaq-Jay, 51100 Reims, France. Electronic address: larissa_komguem@yahoo.fr.
authors.forename: L
authors.initials: L
authors.lastname: Komguem
authors.affiliation: Service de radiothérapie, institut de cancérologie Jean-Godinot, 1, avenue du Général-Koenig, 51100 Reims, France.
authors.forename: P
authors.initials: P
authors.lastname: Guilbert
authors.affiliation: Service de chirurgie, institut de cancérologie Jean-Godinot, 1, avenue du Général-Koenig, 51100 Reims, France.
authors.forename: M
authors.initials: M
authors.lastname: Doublier
authors.affiliation: Service de chirurgie, institut de cancérologie Jean-Godinot, 1, avenue du Général-Koenig, 51100 Reims, France.
authors.forename: F
authors.initials: F
authors.lastname: Guillemin
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage*; D000068878:Trastuzumab / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab; C508053:ERBB2 protein, human
keywords: Breast cancer; Cancer du sein; Chimiothérapie néoadjuvante; Neoadjuvant chemotherapy; Pathologic complete response; Réponse histologique complète; Trastuzumab